Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CATB
  • CUSIP: N/A
  • Web: www.catabasispharma.com
Capitalization:
  • Market Cap: $30.56 million
  • Outstanding Shares: 18,898,000
Average Prices:
  • 50 Day Moving Avg: $1.41
  • 200 Day Moving Avg: $2.46
  • 52 Week Range: $1.08 - $7.89
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.92
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.20 per share
  • Price / Book: 1.13
Profitability:
  • EBIDTA: ($33,720,000.00)
  • Return on Equity: -91.15%
  • Return on Assets: -69.61%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 5.65%
  • Quick Ratio: 5.65%
Misc:
  • Average Volume: 2.00 million shs.
  • Beta: 2.39
  • Short Ratio: 1
 

Frequently Asked Questions for Catabasis Pharmaceuticals (NASDAQ:CATB)

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) issued its quarterly earnings results on Thursday, March, 16th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.02. View Catabasis Pharmaceuticals' Earnings History.

Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2017?

4 analysts have issued 12 month price objectives for Catabasis Pharmaceuticals' stock. Their forecasts range from $4.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $6.25 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.

What are analysts saying about Catabasis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catabasis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (5/19/2017)
  • 2. Wedbush analysts commented, " With numerical improvements in all function-associated endpoints observed in Part B of the MoveDMD trial, we believe extended treatment with edasalonexent (CAT-1004) could result in a deepening of the response'a potential positive sign that could boost shares. We continue to look to Q2:17 for an interim look of the MoveDMD study at 24 weeks (Part C) as the next material catalyst. Q4/FY16 Financial Update: CATB reported no revenues and GAAP EPS (loss) of $(0.47)/$(2.22) vs. consensus of $(0.49)/$(2.25). CATB ended 2016 with ~$38.5 million in cash and cash equivalents and we project runway through Q1:18, in line with company guidance." (3/20/2017)

Are investors shorting Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals saw a decline in short interest in April. As of April 13th, there was short interest totalling 1,288,297 shares, a decline of 25.1% from the March 31st total of 1,721,146 shares. Based on an average daily volume of 386,753 shares, the short-interest ratio is currently 3.3 days. Approximately 13.1% of the company's stock are short sold.

Who are some of Catabasis Pharmaceuticals' key competitors?

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who owns Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SV Health Investors LLC (15.12%), Clarus Ventures LLC (14.56%), Sphera Funds Management LTD. (2.05%), Vanguard Group Inc. (1.95%), Oppenheimer & Co. Inc. (0.48%) and Renaissance Technologies LLC (0.35%). Company insiders that own Catabasis Pharmaceuticals stock include Medimmune Ventures, Inc and Nicholas Galakatos. View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Who bought Catabasis Pharmaceuticals stock? Who is buying Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Oppenheimer & Co. Inc., Renaissance Technologies LLC and Sphera Funds Management LTD.. Company insiders that have bought Catabasis Pharmaceuticals stock in the last two years include Medimmune Ventures, Inc and Nicholas Galakatos. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy Catabasis Pharmaceuticals stock?

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Catabasis Pharmaceuticals stock cost?

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.36.

Analyst Ratings

Consensus Ratings for Catabasis Pharmaceuticals (NASDAQ:CATB) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $6.25 (359.56% upside)

Analysts' Ratings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017WedbushReiterated RatingOurperform$4.00HighView Rating Details
5/15/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$11.00 -> $9.00MediumView Rating Details
3/21/2017HC WainwrightReiterated RatingBuy$14.00 -> $8.00LowView Rating Details
2/1/2017Citigroup IncDowngradeBuy -> NeutralN/AView Rating Details
2/1/2017Cowen and CompanyDowngradeOutperform -> Market Perform$4.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings History by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017Q4 2016($0.49)($0.47)ViewN/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/2/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
8/13/2015Q2 2015($0.70)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)
2017 EPS Consensus Estimate: ($1.49)
2018 EPS Consensus Estimate: ($1.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.35)($0.35)($0.35)
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Ownership Percentage: 64.10%
Institutional Ownership Percentage: 61.43%
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catabasis Pharmaceuticals (NASDAQ:CATB)
Latest Headlines for Catabasis Pharmaceuticals (NASDAQ:CATB)
Source:
DateHeadline
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 19 at 5:20 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM
finance.yahoo.com logoJ&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
finance.yahoo.com - May 18 at 11:24 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.35) Per Share, Wedbush Forecasts (CATB)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share
www.americanbankingnews.com - May 16 at 10:48 AM
americanbankingnews.com logoWedbush Reiterates Ourperform Rating for Catabasis Pharmaceuticals Inc (CATB)
www.americanbankingnews.com - May 15 at 9:34 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Given "Outperform" Rating at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 15 at 10:20 AM
finance.yahoo.com logoEdited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:42 PM
nasdaq.com logoAKTX Falls To Disgrace, CATB Awaits Data In Q3, CORI Surges On Trial Data
www.nasdaq.com - May 12 at 2:48 AM
seekingalpha.com logoCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:47 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma
www.bizjournals.com - May 11 at 9:47 PM
businesswire.com logoCatabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress - Business Wire (press release)
www.businesswire.com - May 11 at 4:45 PM
prnewswire.com logoTechnical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma - PR Newswire (press release)
www.prnewswire.com - May 11 at 4:45 PM
finance.yahoo.com logoInvestor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - May 11 at 4:45 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress
finance.yahoo.com - May 11 at 4:45 PM
finance.yahoo.com logoCatabasis Pharmaceuticals posts 1Q loss
finance.yahoo.com - May 11 at 4:45 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - May 4 at 1:37 AM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Earning Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 12:24 PM
americanbankingnews.com logoShort Interest in Catabasis Pharmaceuticals Inc (CATB) Declines By 25.1%
www.americanbankingnews.com - April 29 at 8:52 AM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Earns Daily News Impact Score of 0.28
www.americanbankingnews.com - April 28 at 11:58 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Catabasis Pharmaceuticals Inc (CATB) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 28 at 8:55 AM
finance.yahoo.com logoCatabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11
finance.yahoo.com - April 27 at 4:34 PM
americanbankingnews.com logoCatabasis Pharmaceuticals' (CATB) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - April 26 at 9:30 PM
streetinsider.com logoCatabasis Pharma (CATB) Announces Positive MoveDMD Trial Results at American Academy of Neurology Meeting - StreetInsider.com
www.streetinsider.com - April 26 at 2:58 PM
streetinsider.com logoCatabasis Pharma (CATB) Announces Positive MoveDMD Trial Results at American Academy of Neurology Meeting
www.streetinsider.com - April 25 at 3:59 PM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Given Daily News Sentiment Score of 0.16
www.americanbankingnews.com - April 25 at 12:38 PM
nasdaq.com logoPre-Market Most Active for Apr 25, 2017 : APFH, AKRX, ESRX, ERIC, CATB, STM, KEP, BAC, SAN, CAT, XIV, NFLX - Nasdaq
www.nasdaq.com - April 25 at 12:21 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Express Scripts, Caterpillar, AdvancePierre - Nasdaq
www.nasdaq.com - April 25 at 12:21 PM
businesswire.com logoCatabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for ... - Business Wire (press release)
www.businesswire.com - April 25 at 12:21 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
finance.yahoo.com - April 25 at 12:20 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 9:42 AM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Given Daily Media Impact Rating of 0.21
www.americanbankingnews.com - April 20 at 4:07 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting
finance.yahoo.com - April 18 at 12:33 PM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Receives News Sentiment Score of 0.04
www.americanbankingnews.com - April 17 at 2:14 PM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Earns Daily Media Impact Rating of 0.26
www.americanbankingnews.com - April 14 at 9:14 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 6 at 10:13 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 28 at 8:08 AM
americanbankingnews.com logoCatabasis Pharmaceuticals' (CATB) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 27 at 9:45 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:02 AM
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Catabasis Pharmaceuticals Inc (CATB)
www.americanbankingnews.com - March 25 at 3:19 PM
finance.yahoo.com logoCATABASIS PHARMACEUTICALS INC Financials
finance.yahoo.com - March 23 at 4:32 PM
americanbankingnews.com logoWedbush Research Analysts Raise Earnings Estimates for Catabasis Pharmaceuticals Inc (CATB)
www.americanbankingnews.com - March 22 at 8:53 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 21 at 6:19 PM
americanbankingnews.com logoOppenheimer Holdings Inc. Analysts Give Catabasis Pharmaceuticals Inc (CATB) a $11.00 Price Target
www.americanbankingnews.com - March 19 at 9:13 PM
finance.yahoo.com logoEdited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT
finance.yahoo.com - March 17 at 4:47 PM
biz.yahoo.com logoQ4 2016 Catabasis Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 16 at 5:26 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 16 at 5:26 PM
biz.yahoo.com logoCATABASIS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:26 PM
biz.yahoo.com logoCatabasis Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 16 at 5:26 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference
finance.yahoo.com - March 15 at 4:30 PM

Social

Chart

Catabasis Pharmaceuticals (CATB) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff